Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.
Journal: Pain and therapy
Published: December 16, 2025
A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
Journal: Headache
Published: January 22, 2025
Safety and efficacy of pegtibatinase enzyme replacement therapy in adults with classical homocystinuria in the COMPOSE phase 1/2 randomized trial.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: January 16, 2025
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study.
Journal: Pain and therapy
Published: August 23, 2024
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Journal: Cephalalgia : an international journal of headache
Published: April 25, 2024
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
Journal: Headache
Published: October 04, 2022
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Journal: The journal of headache and pain
Published: May 17, 2022
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
Journal: Cephalalgia : an international journal of headache
Published: March 25, 2022
Last Updated: 09/26/2026